Signal

Spatial and molecular profiling advances understanding of tumor heterogeneity and therapy resistance

Evidence first: scan the strongest sources, then decide whether to go deeper.

rss
clinical_trialsr_and_dgenomicssafety_signals
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (1 domains)domains are deduped. counts indicate coverage, not truth.
1 top source shown
limited source diversity in top sources
Overview

Recent studies employing spatial transcriptomics, single-cell proteomics, and network-based analyses have deepened insights into tumor microenvironments and molecular evolution across multiple cancers.

Score total
1.29
Momentum 24h
5
Posts
5
Origins
1
Source types
1
Duplicate ratio
0%
Why now
  • New spatial and single-cell technologies enable unprecedented tumor microenvironment resolution.
  • Cross-platform RNA data integration addresses challenges in biomarker reproducibility.
  • Network-based tumor classification supports personalized treatment strategies.
Why it matters
  • Spatial and multiomic profiling reveals tumor heterogeneity critical for precision oncology.
  • Identifying therapy resistance mechanisms guides development of targeted combination treatments.
  • Integrative biomarker discovery across platforms enhances clinical decision-making.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
  • Spatial transcriptomics identifies stage-specific gene expression programs in cutaneous squamous cell carcinoma
  • Imaging mass cytometry reveals multicellular niches linked to prognosis in primary prostate cancer
  • POSTN+ cancer-associated fibroblasts mediate chemoradiotherapy resistance in rectal cancer
  • Cross-assay RNA integration improves biomarker discovery in heterogeneous ovarian cancer
How sources frame it
  • Naji Et Al.: neutral
  • Martinelli Et Al.: neutral
  • Sakai Et Al.: neutral
  • Townsend Et Al.: neutral
All evidence
All evidence
Show filters & breakdown
Posts loaded: 0Publishers: 1Origin domains: 1Duplicates: -
Showing 1 / 0
Top publishers (this list)
  • bioRxiv (all subjects) (1)
Top origin domains (this list)
  • biorxiv.org (1)